NEW STUDY. An international study shows that it is likely that insulin can be stored at room temperature, and for considerably longer than drug companies have counted on to date. Access to this vital medicine can thereby be significantly improved for the world’s poorest inhabitants. Researchers at the University of Gothenburg are among the scientists presenting these results. In type 1 diabetes, the insulin-producing beta cells in the pancreas are…
Wallenberg Centre biophysicist seeks markers for diabetes
YOUNG RESEARCHERS. Joan Camuñas-Soler, the newly appointed Assistant Professor in Bioinformatics for Translational Medicine, has his own research group at the Wallenberg Centre for Molecular and Translational Medicine (WCMTM). In his research, he combines diagnostics, computer science and biophysics to find new biomarkers, currently for metabolic disorders such as diabetes in particular. His Lundberg Laboratory office gives an airy, unadorned impression — hardly surprising, since he has held his research…
Diabetics hit harder by COVID-19
NEW STUDY. People with type 2 diabetes are at significantly elevated risk of needing intensive care if they get COVID-19. This is shown by a study comprising data on 2.6 million Swedes, of whom half a million are on the diabetes register. The study also indicates increased mortality from COVID-19 among type 2 diabetics. In Sweden, about half a million people have diabetes, and 90 percent of them have type…
Good long-term effects of continuous glucose monitoring
NEW STUDY. New data on continuous glucose monitoring for people with type 1 diabetes, over a significantly longer period than before, are now available. A University of Gothenburg study shows that using the CGM tool, with its continuous monitoring of blood sugar (glucose) levels, has favorable effects over several years. The technology of continuous glucose monitoring (CGM) is superseding that of the classic portable blood glucose meters, which require a…
A molecule from gut bacteria reduces effect of diabetes medication
NEW STUDY. The action of metformin, the classic drug used to treat diabetes by stabilizing blood sugar, can be blocked by a molecule from the bacteria in our intestines, a University of Gothenburg study shows. Metformin is the primary treatment option for type 2 diabetes, but there are major variations in how individuals respond to this drug. In some people it lowers blood glucose (sugar) and delays the course of…